In a collaborative effort, Serum Institute of India (SII) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (USA), have come together to create the first-ever heat-stable Rotavirus vaccine in the world.

 

Albert Z. Kapikian, M.D., a pioneering virologist at NIAID defined the mode of transmission of Rotavirus, identified the viral proteins critical for triggering an immune response, and formulated a vaccine that targeted several important Rotavirus strains.

 

In 2005, NIAID and Serum Institute of India Pvt. Ltd. (SIIPL) joined hands for the development of a Rotavirus Vaccine. The collaboration, through a license agreement, aimed at finding a solution that was not just affordable, but would reduce the operational difficulties faced by the poor countries for vaccine distribution and administration. Both parties were cognizant of the fact that the single biggest challenge faced by the distribution channel was the ability to maintain the vaccine under refrigeration. Costs associated with the maintenance of a cold chain can be in the region of 200 Million Dollars a year, which clearly adds to the cost of vaccination.

 

SII worked to develop a heat stable formulation to overcome this problem and Rotasiilis claimed to be the only Rotavirus vaccine to have the ability to withstand extreme temperatures. It can be stored at temperatures up to 25°C throughout its shelf life of 30 months, which makes Rotasiilcompletely unique from other vaccines that require refrigeration for storage and transportation. The vaccine will revolutionize healthcare for children across the globe due to its potency, longevity and ability to endure severe changes in temperature, thereby reducing wastage and storage costs.

 

SII and NIAID, jointly developed the heat-stable Rotasiil and received two prestigious awards in 2018. The Deal of Distinction award was given by Licensing Executive society of US and Canada (LES) for development of ROTASIIL, a low-cost, temperature tolerant Rotavirus vaccine for developing countries in the category of Industry-University-Government Interface (IUGI) Sector. The Patent for Humanity award was given by the United States Patent and Trademark Office.

 

Introduction of the Rotasiilvaccine, with its long shelf life and lack of need for refrigeration, is a timely boon for millions affected by Rotavirus. SII and NIAID’s joint endeavor in creating the heat-stable Rotasiil vaccine effectively fills the need, reducing costs and relieving bottlenecks in the vaccine supply-chain.

 

This breakthrough invention has also been awarded a patent for being the first-of-its-kind thermostable Rotavirus vaccine by United States Patent and Trademark Office (USPTO).

 

In addition to the patent, Rotasiilhas also been assigned the VVM 250 label, which had to be specially developed for Rotasiil for its high heat stability. Accepted by the World Health Organization (WHO), the VVM250 label on Rotasiil helps immunization managers across the world to store it at room temperature, while allowing excursion in temperatures during storage and transportation up to 39°C.

 

Adar Poonawalla, CEO of SII,commenting about this development said, “Providing a healthy life to their children is the dream of every parent, and the thermo stabilizing of the Rotasiil® vaccine is one step towards that direction. Among all the barriers that led to decreasing of vaccine potency, heat-instability ranks highest causing the vaccine to become ineffective and therefore increasing wastage. Rotasiil will help reduce misapplication, wastefulness, cost for logistics, increase availability and therefore, help millions more, lead a healthier life.”

Rotasiil is claimed to be the only Rotavirus vaccine to have the ability to withstand extreme temperatures. It can be stored at temperatures up to 25°C throughout its shelf life of 30 months.